PIK3CA
PIK3CA mutations activate the PI3K signaling pathway. These alterations are actionable in breast and other cancers.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where PIK3CA is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Breast Cancer Solid Tumor · Breast |
|
Approvals defined at the solid tumor level where PIK3CA is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report PIK3CA as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports PIK3CA as part of its biomarker panel.
Reports PIK3CA as part of its biomarker panel.
Reports PIK3CA as part of its biomarker panel.
Reports PIK3CA as part of its biomarker panel.